Phenylpropylaminopentane

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 14:53, 15 November 2016 (→‎top: clean up; http→https for Google Books and other Google services using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Phenylpropylaminopentane
Legal status
Legal status
Identifiers
  • (R)-1-Phenyl-N-propylpentan-2-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC14H23N
Molar mass205.345 g·mol−1
3D model (JSmol)
  • CCCN[C@H](CCC)Cc1ccccc1
  • InChI=1S/C14H23N/c1-3-8-14(15-11-4-2)12-13-9-6-5-7-10-13/h5-7,9-10,14-15H,3-4,8,11-12H2,1-2H3/t14-/m1/s1
  • Key:PBENSVGEGPJNFJ-CQSZACIVSA-N

(-)-1-Phenyl-2-propylaminopentane (also known as (-)-PPAP and N,α-dipropylphenethylamine)[1][2][3] is a stimulant of the phenethylamine and amphetamine classes with an unusual effects profile and mechanism of action.[4]

(-)-PPAP is classified as a monoaminergic activity enhancer that stimulates the impulse propagation mediated transmitter release of the neurotransmitters dopamine, norepinephrine and serotonin in the brain. Unlike stimulants such as amphetamine, which release a flood of monoamine neurotransmitters in an uncontrolled manner, (-)-PPAP instead only increases the amount of neurotransmitters that get released when a neuron is stimulated by receiving an impulse from a neighbouring neuron. Both amphetamine and (-)-PPAP promote the release of monoamines and deuteramines, however while amphetamine causes neurons to dump neurotransmitter stores into the synapse regardless of external input, (-)-PPAP does not influence the pattern of neurotransmitter release and instead releases a larger amount of neurotransmitters than normal.[5]

(-)-PPAP has no monoamine oxidase inhibitory activity.[6]

See also

References

  1. ^ Jozsef Knoll (15 June 1993). "Patent US 5220068 - Psychostimulant agent".
  2. ^ Fumio Yoneda (10 April 2001). "Patent US 6214859 - Ethylamine derivatives".
  3. ^ Jozsef Knoll (24 December 2001). "Patent US 5075338 - Method of treatment of learning deficiency".
  4. ^ Knoll J, Knoll B, Török Z, Timár J, Yasar S (March–April 1992). "The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant". Archives internationales de Pharmacodynamie et de Thérapie (316): 5–29. PMID 1356324.
  5. ^ Joseph Knoll; Ildikó Miklya; Berta Knoll; Raissa Markó; Károly Kelemen (February 1996). "(−)Deprenyl and (−)1-phenyl-2-propylaminopentane, [(−) PPAP] act primarily as potent stimulants of action potential — transmitter release coupling in the catecholaminergic neurons". Life Sciences. 58 (10): 817–827. doi:10.1016/0024-3205(96)00014-8. PMID 8602114.
  6. ^ G. Csaba; P. Kovács; Éva Pállinger (January–February 2006). "Acute and delayed effect of (−) deprenyl and (−) 1-phenyl-2-propylaminopentane (PPAP) on the serotonin content of peritoneal cells (white blood cells and mast cells)". Cell Biochemistry and Function. 24 (1): 49–53. doi:10.1002/cbf.1183. PMID 15584092.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Phenylpropylaminopentane&oldid=749654896"